To the Editor,
We have read with interest the review by Ryken et al. about the role of imaging in the management of progressive glioblastoma [1] . In general, we agree with this review but we cannot support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify progression of glioblastoma is not recommendable.
The authors have considered PET using the amino acid tracer 11 C-methyl-L-methionine (MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short half-life of 11 C (20.4 min). In recent years, the clinical application of 18 F-labeled amino acids such as O- (2- 18 F-fluoroethyl)-L-tyrosine (FET) or 3,4-dihydroxy-6-[ 18 F]fluoro-L-phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18 F label (half-life, 109.8 min) [2] . FET can be produced with high yields similar to the widely used FDG and distributed in a satellite concept [3] . In Europe, MET PET has been replaced in many centers by the more convenient PET tracer FET, which is now established as a routine tool for brain tumor imaging in more than 30 neuro-oncological centers in Germany, Austria and Switzerland (personal communication). In these countries, the clinical acceptance is high and more than 10.000 FET PET scans in brain tumor patients have been performed alone in the centers in Jülich, Munich and Zurich in the last years.
The diagnostic accuracy of FET PET in the differentiation of tumor progression or recurrence from radiationinduced changes is convincing. A sensitivity and specificity of FET PET for the detection of tumor progression or recurrence of 100 and 93 %, respectively, has been reported, compared with 93 and 50 % for MRI alone [4] . The additional use of dynamic FET PET allows a differentiation of high-grade and low-grade recurrences with a sensitivity and specificity of [90 % [5] . Similar results have also been reported for the differentiation of recurrent brain metastases from radiation-induced changes with an accuracy of 93 % [6] . Furthermore, a prospective study evaluated the prognostic value of early changes of FET uptake after postoperative radiochemotherapy in patients with glioblastoma [7] . PET responders with a decrease of the tumor/brain ratio of FET uptake of more than 10 % had a significantly longer disease-free survival and overall survival than patients with stable or increasing tracer uptake after radiochemotherapy. Additionally, a reliable treatment monitoring was also demonstrated in various experimental approaches (e.g., radioimmunotherapy [8] , convection enhanced delivery of paclitaxel [9] ) and for antiangiogenic treatment with bevacizumab and irinotecan [10, 11] .
Using FDOPA PET, a recent study including 110 patients reported an accuracy of 82 % to detect recurrent glioblastoma and FDOPA uptake was a significant predictor of progression-free survival [12] . Excellent results with FDOPA PET were also reported regarding the monitoring of antiangiogenic treatment and for the differentiation of recurrent brain metastases from radiation-induced changes.
Moreover, we would like to point out that the excellent results of single-photon-emission-tomography (SPECT) with respect to differentiation of tumor recurrence mentioned in the review of Ryken et al. is based on the use of the amino acid tracer L-3-[
123 I]iodo-a-methyl-tyrosine (IMT), which delivers similar results as FET PET but at lower spatial resolution [13] .
In summary, we consider PET using 18 F-labelled amino acids such as FET or FDOPA as one of the most promising imaging methods in the management of progressive glioblastoma. In the review by Ryken and colleagues, this recent development has not been adequately addressed.
